RespiPoints Digital Patient Support Programme Now Open to Patients Taking One of Three Boehringer Ingelheim Medicines
24 April 2018 - - Ridgefield, Connecticut-based Boehringer Ingelheim Pharmaceuticals, the largest US subsidiary of Boehringer Ingelheim Corp., and Norwak, Connecticut-based HealthPrize Technologies have expanded the RespiPoints digital support programme to anyone taking one of several Boehringer Ingelheim medicines, including select medicines available in the Respimat inhaler, the companies said.
The RespiPoints program is a free web and mobile-based program that engages and rewards patients through education about their condition and support to take their medicines daily as prescribed by their healthcare provider.
Patients enrolled in the RespiPoints program participate in a variety of activities to earn points, which can be redeemed for e-gift cards. Activities include reporting daily medicine taking, verifying monthly refills, reading educational information and insightful tips and completing weekly quizzes and surveys.
Patients who participated in the nine-month pilot of the RespiPoints program showed an 85% decrease in gap days between refilling their next prescription after beginning RespiPoints; monthly engagement with the RespiPoints website averaged 4.6 visits and an average of 50 minutes per month.
Seventy-one percent of RespiPoints participants said they would be "very likely" to recommend RespiPoints to a friend or family member, and 56% of participants remained active in RespiPoints over the entire nine-month pilot period.
Life science companies worldwide use HealthPrize's technology to develop digital patient experiences that enhance revenue by improving adherence, increasing health literacy, and providing brand differentiation.
The company's gamification- and behavioral economics-based platform powers and advances patient engagement for branded and generic medications across all therapeutic areas, demographics and drug delivery methods.
Boehringer Ingelheim Pharmaceuticals is the largest US subsidiary of Boehringer Ingelheim Corp., headquartered in Ingelheim, Germany.
The company operates globally with approximately 50,000 employees in three business areas including human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing.